Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.6 USD | -0.73% |
|
-.--% | +12.17% |
06-25 | Recordati acquires its own shares for approximately EUR3 million | AN |
06-18 | Recordati acquires treasury shares for more than EUR4 million | AN |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.17% | 10.63B | - | ||
+55.32% | 819B | C+ | ||
-6.75% | 351B | C+ | ||
+13.56% | 329B | B- | ||
+10.68% | 298B | C+ | ||
+16.57% | 242B | B+ | ||
+2.04% | 225B | A+ | ||
+13.31% | 217B | B- | ||
+8.48% | 168B | C+ | ||
-2.81% | 158B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- REC Stock
- RCDTF Stock
- Ratings Recordati